**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 58557

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Predictive factors for early distant metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer**

Park H. Predictive factors for early distant metastasis

Hyojung Park

**Hyojung Park,** Departments of Radiation Oncology, Dankook University Hospital, Dankook University College of Medicine, Cheonan 46115, South Korea

**Author contributions:** Park H analyzed the data and wrote the manuscript.

**Corresponding author: Hyojung Park, MD, Doctor,** Departments of Radiation Oncology, Dankook University Hospital, Dankook University College of Medicine, 201 Manghyang-ro, Dongnam-gu, Cheonan 46115, South Korea. hj0714.park@dkuh.co.kr

**Received:** September 10, 2020

**Revised:** January 11, 2021

**Accepted:** March 16, 2021

**Published online:**

**Abstract**

BACKGROUND

Distant relapse is the leading cause of cancer-related death in locally advanced rectal cancer. Neoadjuvant chemoradiation (NACRT) followed by surgery inevitably delays delivery of systemic treatment. Some patients show early distant metastasis before systemic treatment.

AIM

To identify the most effective treatments. We investigated prognostic factors for distant metastasis, especially early distant metastasis, using the standard treatment paradigm to identify the most effective treatments according to recurrence risk.

METHODS

From January 2015 through December 2019, rectal cancer patients who underwent NACRT for having clinical T 3-4 or clinical N 1-2 disease according to the 8th American Joint Committee on Cancer staging system were included. Radiotherapy was delivered to the whole pelvis with concomitant chemotherapy. Patients received surgery 6-8 wk after completion of NACRT. Adjuvant chemotherapy was administered at the physician’s discretion.

RESULTS

A total of 127 patients received NACRT. Ninety-three patients (73.2%) underwent surgery. The R0 resection rate was 89.2% in all patients. Pathologic tumor and node downstaging rates were 41.9% and 76.3%. Half the patients (*n* = 69) received adjuvant chemotherapy after surgery. The 3-year distant metastasis-free survival (DMFS) and overall survival (OS) rates were 81.7% and 83.5%. On univariate analyses, poorly differentiated tumors, > 5 cm, involvement of mesorectal fascia (MRF), or presence of extramural involvement (EMVI) were associated with worse DMFS and OS. Five patients showed distant metastasis at their first evaluation after NACRT. Patients with early distant metastasis were more likely to have poorly differentiated tumor (*P* = 0.025), tumors with involved MRF (*P* = 0.002), and EMVI (*P* = 0.012) than those who did not.

CONCLUSION

EMVI, the involvement of MRF, and poor histologic grade were associated with early distant metastasis. In order to control distant metastasis and improve treatment outcome, selective use of neoadjuvant treatment according to individualized risk factors is necessary. Future studies are required to determine effective treatment strategies for patients at high risk for distant metastasis.

**Key Words:** Rectal cancer; Neoadjuvant chemoradiotherapy; Distant metastasis; Extramural venous invasion

Park H. Predictive factors for early distant metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *World J Gastrointest Oncol* 2021; In press

**Core Tip:** This is a retrospective study to investigate prognostic factors for distant metastasis, especially early distant metastasis, using the standard treatment paradigm to identify the most effective treatments according to recurrence risk. Poorly differentiated tumors, involvement of mesorectal fascia, or presence of extramural involvement were associated with distant metastasis and early distant metastasis. For patients with these risk factors, early systemic chemotherapy could be beneficial. Selective use of neoadjuvant treatment other than the current standard treatment according to individualized risk factors is necessary.

**INTRODUCTION**

The management of locally advanced rectal cancer has improved in recent decades. Surgery quality and approach have improved, and pelvic radiotherapy and chemotherapy have been incorporated into standard treatments. Management of locally advanced rectal cancer, however, remains challenging in most cases. Before pelvic radiotherapy, local recurrence was a common pattern of treatment failure. Along with total mesorectal excision (TME), neoadjuvant chemoradiation (NACRT) has decreased the local recurrence (LR) rate from 35% to less than 10%[[1](#_ENREF_1)]. Although NACRT has contributed to decreased local recurrence, distant relapse rates have not changed, and remain at approximately 30% in locally advanced rectal cancer. Currently, distant relapse is the leading cause of cancer-related death in rectal cancer patients[[2](#_ENREF_2)].

Adjuvant chemotherapy has been recommended as a systemic treatment in patients with locally advanced rectal cancer treated with NACRT and surgery, but its efficacy remains controversial due to poor compliance and unclear survival benefit[[2](#_ENREF_2)]. Another problem is that some patients show early distant metastasis before systemic treatment. NACRT followed by surgery, which is the current standard treatment for patients with locally advanced rectal cancer, inevitably delays delivery of systemic treatment. Early systemic treatments prior to surgery have been proposed to improve systemic control. Several randomized trials and observational studies have integrated systemic chemotherapy into neoadjuvant treatment to overcome systemic treatment delay, thereby reducing distant relapse and increasing treatment compliance[[2](#_ENREF_2)]. Some studies have incorporated chemotherapy prior to NACRT while others omitted radiotherapy from neoadjuvant treatment paradigms[[3-24](#_ENREF_3)].

The treatment sequence for multimodality treatment should be individualized according to patient age, comorbidities, stage, and tumor characteristics. Prognostic factors for distant metastasis and patient characteristics, such as eligibility, were different across studies. Therefore, we investigated prognostic factors for distant metastasis, especially early distant metastasis, using the standard treatment paradigm to identify the most effective treatments according to recurrence risk.

**MATERIALS AND METHODS**

***Patients and initial evaluations***

This study was approved by the Institutional Review Board of Dankook University Hospital (DKUH 2020-08-26). The authors retrieved data from 148 consecutive rectal cancer patients from January 2015 through December 2019 who underwent NACRT for clinical T (cT) 3-4 or clinical N (cN) 1-2 disease according to the 8th American Joint Committee on Cancer staging system. Patients with resectable metastatic disease were included because aggressive local treatment and metastasectomy can be curative. Patients were excluded if they did not complete NACRT, had no imaging evaluation after NACRT, had multiple malignant tumors or had unresectable metastatic disease. Pretreatment evaluations for diagnostic confirmation and clinical stage assignment included a complete history and physical examination, complete blood counts, blood chemistry profiles, carcinoembryonic antigen, colonoscopy with biopsy, and computed tomography (CT) of the chest and abdomen/pelvis. Magnetic resonance imaging (MRI) of the rectum was performed in 91 patients (71.1%), and whole-body 18F-fluorodeoxyglucose positron emission tomography with CT was performed in 90 patients (70.3%). Size and shape criteria for diagnosing lymph-node metastasis were as follows[[25](#_ENREF_25)]: Short-axis length ≥ 5 mm; if short-axis length < 5 mm, additional criteria, such as round shape, heterogeneity of appearance, irregular border, presence of mucin and/or calcifications, or loss of the normal fatty hilum, were evaluated.

***Treatment***

All patients underwent CT scans with a belly board before setting a radiotherapy plan. Among all patients, 117 (92.1%) were treated with 3-dimensional conformal radiotherapy (3D-CRT) and 10 (10.0%) were treated with intensity-modulated radiotherapy. Radiotherapy was delivered to the whole pelvis at a dose of 45 Gy with 1.8 Gy *per* fraction for five weeks, five days *per* week. The boost dose was delivered to the gross tumor at a dose of 5.4 Gy with 1.8 Gy *per* fraction. During the radiotherapy course, concomitant chemotherapy was given as capecitabine 825 mg/m2 twice daily on radiotherapy days. Patients were assessed weekly for toxicity during CRT. Patients received surgery 6-8 wk after completion of NACRT. Adjuvant chemotherapy was administered at the physician’s discretion. Adjuvant chemotherapy commenced 6-8 wk after surgery.

***Surveillance and statistical analyses***

The first follow-up evaluations included physical examination, blood tests, colonoscopy with or without biopsy, and abdominopelvic CT or MRI of the rectum 6-8 wk after NACRT completion. After the planned treatment, regular follow-up evaluations were scheduled at 3 mo intervals for the first 2 years and then at 6 mo intervals thereafter. LR recurrence was defined as relapse within the RT target volume or regional lymphatics. Distant metastasis was defined as relapse other than LR recurrence including peritoneal seeding and hematogenous metastasis. Survival durations was calculated from the date of treatment until the date of event (death or relapse) or the date of the latest follow-up. The rates of overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were calculated using the Kaplan-Meier method, and comparisons between subgroups were performed using the log-rank test. Cox proportional hazard regression analysis was used to determine the independent prognostic factors. For group comparisons, categorical variables were compared usingthechi-square test or Fisher’s exact test. Continuous variables were compared using the t-test or the Mann-Whitney test. All *P* values were two-sided, and *P* < 0.05 were considered statistically significant throughout the study. Statistical analyses were performed using SPSS software, standard version 26.0 (IBM Corporation, Armonk, NY, United States).

**RESULTS**

***Patient characteristics***

A total of 127 patients received NACRT from 2015 to 2019 (Table 1). The median age of all patients was 65 (27-92) years. Three patients (2.4%) had poorly differentiated tumors. Most patients had cT3, cT4, or positive lymph nodes. Patients with cT3 disease were divided into the following subcategories: cT3a (*n* = 22), cT3b (*n* = 24), cT3c (*n* = 21), and cT3d (*n* = 27). Nine patients (7.1%) showed mesorectal fascia (MRF) involvement. MRI of the rectum was used, to evaluate the presence of extramural venous invasion (EMVI), and 41 patients (32.3%) showed EMVI. Seven patients had metastatic disease at diagnosis. Thirty-four patients (26.8%) did not undergo surgery for the following reasons: Endoscopic complete remission (CR) after NACRT (*n* = 12), refused surgery (*n* = 17), unfit for surgery due to poor performance status or underlying medical disease (*n* = 2), progressive disease after NACRT (*n* = 2), or expectation of incomplete resection (*n* = 1). Among the 17 patients who refused surgery, nine had tumors within 5 cm from the anal verge or were expected to have an abdominoperineal resection. Five patients refused surgery because of their old age, and three patients refused surgery for other personal reasons. Ninety-three patients underwent surgery: 80 received a scheduled surgery and the remaining 13 received delayed surgery due to refusal (*n* = 4), disease progression (*n* = 2), disease progression after endoscopic CR (*n* = 5), and upfront chemotherapy because of metastatic disease at the first diagnosis. Half the patients (*n* = 69) received adjuvant chemotherapy after surgery. The most common regimen was FOLFOX (*n* = 35), followed by 5-fluorouracil with leucovorin (*n* = 18) and capecitabine (*n* = 16). The compliance rate was 84.1% (*n* = 58). Ten patients could not complete treatment or received a reduced dose.

***Treatment outcomes and prognostic factors***

After NACRT, 124 patients (97.7%) showed a clinical response in image evaluation. Among the 123 patients who received colonoscopy after NACRT, 61 showed chronic inflammation, ulceration, or no tumor on colonoscopic biopsy. The median interval between the last day of NACRT and surgery was 10.2 wk (range: 1.9-96.1 wk) for all patients and 10 wk (range: 1.9-17.7 wk) for patients who received scheduled surgery. The R0 resection rate was 89.2% in all patients and 90.2% in patients who received scheduled surgery. Pathologic tumor and node downstaging rates were 41.9% and 76.3% in all patients, and 42.7% and 76.8% in patients who received scheduled surgery, respectively (Table 2). Three patients showed CR after surgery.

During the median follow-up duration of 21 mo (range: 3-58.5 mo), 9 patients (7.1%) showed LR, 16 patients (12.6%) showed distant metastasis, and 9 patients (7.1 %) died. The LRC, DMFS, DFS and OS rates at 3 years were 90.1%, 81.7%, 75.8%, and 83.5%, respectively. On univariate analyses, poorly differentiated tumors [hazard ratio (HR) = 10.312, *P* = 0.044], tumors > 5 cm (HR = 4.173, *P* = 0.033), and MRF involvement (HR = 11.428, *P* = 0.023) were associated with worse LRC (Table 3). Poorly differentiated tumors, > 5 cm, involvement of MRF, cT3c or d, or presence of EMVI were associated with worse DMFS, DFS, and OS.

***Predictive factors for early distant metastasis***

Five patients showed distant metastasis at their first evaluation after NACRT: Two patients received chemotherapy followed by surgery, one patient received scheduled surgery due to obstructive symptoms, and two patients received chemotherapy only. Patients with early distant metastasis were more likely to have a poorly differentiated tumor (*P* = 0.025) and a proximally located tumor (*P* = 0.031) than those who did not (Table 4). The proportion of patients with tumors with involved MRF (*P* = 0.002) and EMVI (*P* = 0.012) was higher in patients with early distant metastasis.

**DISCUSSION**

A multimodality treatment that comprises NACRT followed by TME and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard treatment for patients with locally advanced rectal cancer[[20](#_ENREF_20)]. NACRT has led to significant improvements in the local control of locally advanced rectal cancer[[26](#_ENREF_26)]. In contrast, control of distant relapse has not changed and is part of the predominant pattern of treatment failure in locally advanced rectal cancer cases receiving the current standard treatment paradigm[[2](#_ENREF_2)]. Although adjuvant chemotherapy is given as a systemic treatment after surgery, compliance with adjuvant chemotherapy has been poor. Approximately half of patients who are eligible for adjuvant chemotherapy initiate treatment after a significant delay or do not receive planned chemotherapy[[26](#_ENREF_26),[27](#_ENREF_27)]. The long-term treatment outcomes from these strategies have been disappointing, thus, a more effective systemic treatment is required[[2](#_ENREF_2),[20](#_ENREF_20)].

Historically, lymph node metastasis and ≥ T3 were known histopathological risk factors for distant metastasis[[8](#_ENREF_8)]. Along with advancements in imaging techniques, locally advanced rectal cancers can be subdivided based on histopathological features, including depth of spread or vascular invasion. The involvements of MRF and EMVI has been shown to be an important prognostic factor, associated with a higher rate of distant metastasis and poorer survival[[5](#_ENREF_5),[8](#_ENREF_8),[24](#_ENREF_24)]. Similarly, the current study showed that involvement of MRF, EMVI, tumor size, and tumor grade were associated with distant metastasis. In the current study, among these factors, MRF, EMVI and tumor grade were associated with early distant metastasis, which occurred during the interval between completion of NACRT and surgery. Early distant metastasis is associated with poor survival[[28](#_ENREF_28)]. Therefore, patients with these risk factors should be treated with more aggressive treatment before surgery. These findings suggest that not all rectal cancer patients need NACRT before surgery, and a more individualized treatment approach should be taken that is tailored to the patient’s risk factors at baseline. This individualized approach to treatment could lead to excellent oncological outcomes.

Several studies have suggested that early full-dose chemotherapy should be incorporated into neoadjuvant treatment (Tables 5 and 6). The inclusion criteria varied widely between the studies and most studies, and most studies included ≥ T3, lymph node metastasis, the involvement of MRF, or EMVI. Early distant metastasis may be present in the form of micrometastatic foci at the time of initial diagnosis[[28](#_ENREF_28)]. The disadvantage of NACRT is that systemic chemotherapy is delayed, which may allow the spread and growth of distant micrometastases that may already exist. Early systemic chemotherapy may benefit patients who have a high potential for early distant metastasis, treat such micrometastatic disease and potentially reduce the distant relapse rate[[1](#_ENREF_1)]. Another advantage of early chemotherapy is the delivery of an effective dose of chemotherapy using an intact vasculature that has not been disrupted by radiotherapy or surgery. Additionally, early chemotherapy induces tumor vascularity due to tumor shrinkage, allowing for improved oxygenation, which may offer improved sensitivity to chemotherapy or radiotherapy[[29](#_ENREF_29)]. Early chemotherapy may also increase patient compliance to systemic chemotherapy, which is the primary weakness of adjuvant chemotherapy[[7](#_ENREF_7)]. Another benefit is that the time to temporary ostomy reversal is shorter when no adjuvant chemotherapy is planned[[26](#_ENREF_26)]. Early systemic chemotherapy, however, delays surgery and reduces radiotherapy efficacy due to the selective survival of radioresistant clones[[7](#_ENREF_7),[29](#_ENREF_29)].

Among early chemotherapy studies, several studies have reported treatment outcomes of neoadjuvant chemotherapy (NAC) alone followed by surgery (Table 6). Advancements in surgical techniques have led to significant improvements in local control and have made LR a rare event. Additionally, increasing awareness of potential radiotherapy related risks, such as urinary and sexual dysfunction, and intestinal problems, has led physicians to omit radiotherapy[[23](#_ENREF_23)]. This treatment strategy also has the benefit of short treatment duration. Several studies showed comparable results to standard treatment, with pathologic CR rates ranging from 6%-27%[[12](#_ENREF_12),[17-24](#_ENREF_17)]. However, these promising results are not enough to evaluate whether this treatment was effective in reducing distant metastasis. Additionally, omitting radiotherapy should be considered carefully. The advantage of incorporating radiotherapy into neoadjuvant treatment paradigms includes an increased likelihood of R0 resection, reduced risk of tumor seeding, enhanced radiosensitivity due to intact vasculature, and an increased chance of sphincter preservation surgery[[12](#_ENREF_12)]. In a Chinese randomized trial, patients who received NAC without radiotherapy showed a lower pathologic CR rate and a higher lymph node metastasis rate than patients who received NAC with radiotherapy[[20](#_ENREF_20)]. Further studies are ongoing[[1](#_ENREF_1)].

This study has several limitations. The number of patients who received MR imaging was small. MR imaging allows accurate prediction of MRF involvement and EMVI[[30](#_ENREF_30)]. However, in another study, approximately 30%-40% of rectal cancer patients had baseline EMVI positivity on MR images, which is similar to the findings of this study[[24](#_ENREF_24)]. This suggests that the proportion of underestimated EMVI may not be high. This study also observed lower pathologic CR rates than other studies of NACRT with capecitabine. The low rate of scheduled surgical resection may affect the poor pathologic CR rate. Due to the inherent nature of retrospective data, selection bias is an important consideration. Despite these limitations, an important strength of this study is that it includes a homogenous group of patients.

**CONCLUSION**

The results of this study showed that EMVI, the involvement of MRF, and poor histologic grade were associated with early distant metastasis. For patients with these risk factors, early systemic chemotherapy could be beneficial. To control distant metastasis and improve treatment outcomes, selective use of neoadjuvant treatment according to individualized risk factors in addition to the current standard treatment is necessary. Future studies that include carefully applied imaging and randomized design are required to determine effective treatment strategies for patients at high risk for distant metastasis. Several clinical trials are ongoing and awaiting results, thus, development of a reliable method to select patients is necessary.

**ARTICLE HIGHLIGHTS**

***Research background***

Distant relapse has become the leading cause of cancer death in locally advanced rectal cancer. The standard treatment of locally advanced rectal cancer, neoadjuvant chemoradiation (NACRT) followed by surgery, inevitably delays delivery of systemic treatment.

***Research motivation***

This study investigated prognostic factors for distant metastasis, especially early distant metastasis, using the standard treatment paradigm to identify the most effective treatments according to recurrence risk.

***Research objectives***

We investigated prognostic factors for early distant metastasis, using the standard treatment paradigm to identify the most effective neoadjuvant treatments according to recurrence risk.

***Research methods***

The authors retrieved data from 148 consecutive rectal cancer patients from January 2015 through December 2019 who underwent NACRT for having clinical T 3-4 or clinical N 1-2 disease according to the 8th American Joint Committee on Cancer staging system.

***Research results***

Patients with early distant metastasis were more likely to have poorly differentiated tumor (*P* = 0.025), tumors with involved mesorectal fascia (*P* = 0.002), and extramural venous invasion (*P* = 0.012) than those who did not. Due to the small number of patients who received magnetic resonance imaging and inherent limitation of retrospective study, prospective studies with large number of patients are needed.

***Research conclusions***

For patients with risk factors for early distant metastasis, early systemic chemotherapy could be beneficial. According to the risk factors, neoadjuvant treatment should be individualized.

***Research perspectives***

Future studies that include carefully applied imaging and randomized design are required.

**REFERENCES**

1 **Bossé D**, Mercer J, Raissouni S, Dennis K, Goodwin R, Jiang D, Powell E, Kumar A, Lee-Ying R, Price-Hiller J, Heng DY, Tang PA, MacLean A, Cheung WY, Vickers MM. PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium. *Clin Colorectal Cancer* 2016; **15**: 243-249 [PMID: 26964803 DOI: 10.1016/j.clcc.2016.02.003]

2 **Yoo RN**, Kim HJ. Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy. *Ann Gastroenterol Surg* 2019; **3**: 356-367 [PMID: 31346574 DOI: 10.1002/ags3.12253]

3 **Chau I**, Allen M, Cunningham D, Tait D, Brown G, Hill M, Sumpter K, Rhodes A, Wotherspoon A, Norman AR, Hill A, Massey A, Prior Y. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. *Br J Cancer* 2003; **88**: 1017-1024 [PMID: 12671697 DOI: 10.1038/sj.bjc.6600822]

4 **Chua YJ**, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. *Lancet Oncol* 2010; **11**: 241-248 [PMID: 20106720 DOI: 10.1016/S1470-2045(09)70381-X]

5 **Chau I**, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *J Clin Oncol* 2006; **24**: 668-674 [PMID: 16446339 DOI: 10.1200/JCO.2005.04.4875]

6 **Fernandez-Martos C**, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD. Chemoradiation, surgery and adjuvant chemotherapy *vs* induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. *Ann Oncol* 2015; **26**: 1722-1728 [PMID: 25957330 DOI: 10.1093/annonc/mdv223]

7 **Fernández-Martos C**, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. *J Clin Oncol* 2010; **28**: 859-865 [PMID: 20065174 DOI: 10.1200/JCO.2009.25.8541]

8 **Gollins S**, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, Saunders M, Quirke P, Ray R, Parsons P, Griffiths G, Maughan T, Adams R, Hurt C. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. *Br J Cancer* 2018; **119**: 697-706 [PMID: 30116024 DOI: 10.1038/s41416-018-0209-4]

9 **Perez K**, Safran H, Sikov W, Vrees M, Klipfel A, Shah N, Schechter S, Oldenburg N, Pricolo V, Rosati K, Dipetrillo T. Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study. *Am J Clin Oncol* 2017; **40**: 283-287 [PMID: 25374145 DOI: 10.1097/COC.0000000000000149]

10 **Schou JV**, Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, Nielsen DL, Vistisen K, Fromm A, Jensen BV. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. *Ann Oncol* 2012; **23**: 2627-2633 [PMID: 22473488 DOI: 10.1093/annonc/mds056]

11 **Dueland S**, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K. Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. *Clin Oncol (R Coll Radiol)* 2016; **28**: 532-539 [PMID: 26888115 DOI: 10.1016/j.clon.2016.01.014]

12 **Koeberle D**, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. *Br J Cancer* 2008; **98**: 1204-1209 [PMID: 18349837 DOI: 10.1038/sj.bjc.6604297]

13 **Maréchal R**, Vos B, Polus M, Delaunoit T, Peeters M, Demetter P, Hendlisz A, Demols A, Franchimont D, Verset G, Van Houtte P, Van de Stadt J, Van Laethem JL. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. *Ann Oncol* 2012; **23**: 1525-1530 [PMID: 22039087 DOI: 10.1093/annonc/mdr473]

14 **Dewdney A**, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *J Clin Oncol* 2012; **30**: 1620-1627 [PMID: 22473163 DOI: 10.1200/JCO.2011.39.6036]

15 **Nogué M**, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C; AVACROSS Study Group. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. *Oncologist* 2011; **16**: 614-620 [PMID: 21467148 DOI: 10.1634/theoncologist.2010-0285]

16 **Eisterer W**, Piringer G, DE Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. *Anticancer Res* 2017; **37**: 2683-2691 [PMID: 28476845 DOI: 10.21873/anticanres.11617]

17 **Koizumi M**, Yamada T, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Hara K, Ohta K, Uchida E, Yoshida H. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. *In Vivo* 2018; **32**: 937-943 [PMID: 29936483 DOI: 10.21873/invivo.11332]

18 **Zhang J**, Huang M, Cai Y, Wang L, Xiao J, Lan P, Hu H, Wu X, Ling J, Peng J, Chen D, Kang L, Zhang Y, Ren D, Wang H, Chen S, Lin F, Zheng J, Zhou Z, Wang J, Deng Y. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer. *Clin Colorectal Cancer* 2019; **18**: 238-244 [PMID: 31378655 DOI: 10.1016/j.clcc.2019.07.001]

19 **Ishii Y**, Hasegawa H, Endo T, Okabayashi K, Ochiai H, Moritani K, Watanabe M, Kitagawa Y. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. *Eur J Surg Oncol* 2010; **36**: 1061-1065 [PMID: 20538422 DOI: 10.1016/j.ejso.2010.05.017]

20 **Deng Y**, Chi P, Lan P, Wang L, Chen W, Cui L, Chen D, Cao J, Wei H, Peng X, Huang Z, Cai G, Zhao R, Huang Z, Xu L, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Zhou Z, Cai Y, Kang L, Huang M, Peng J, Ren D, Wang J. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. *J Clin Oncol* 2016; **34**: 3300-3307 [PMID: 27480145 DOI: 10.1200/JCO.2016.66.6198]

21 **Deng Y**, Chi P, Lan P, Wang L, Chen W, Cui L, Chen D, Cao J, Wei H, Peng X, Huang Z, Cai G, Zhao R, Huang Z, Xu L, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Zhou Z, Cai Y, Kang L, Huang M, Wu X, Peng J, Ren D, Wang J. Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. *J Clin Oncol* 2019; **37**: 3223-3233 [PMID: 31557064 DOI: 10.1200/JCO.18.02309]

22 **Schrag D**, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol* 2014; **32**: 513-518 [PMID: 24419115 DOI: 10.1200/JCO.2013.51.7904]

23 **Uehara K**, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, Tojima Y, Yoshioka Y, Nakayama G, Yatsuya H, Ohmiya N, Goto H, Nagino M. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. *Jpn J Clin Oncol* 2013; **43**: 964-971 [PMID: 23935207 DOI: 10.1093/jjco/hyt115]

24 **Patel UB**, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. *Ann Oncol* 2017; **28**: 344-353 [PMID: 28426108 DOI: 10.1093/annonc/mdw616]

25 **Matalon SA**, Mamon HJ, Fuchs CS, Doyle LA, Tirumani SH, Ramaiya NH, Rosenthal MH. Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy. *Radiographics* 2015; **35**: 2090-2107 [PMID: 26562239 DOI: 10.1148/rg.2015150037]

26 **Cercek A**, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, Garcia-Aguilar J, Saltz LB. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. *J Natl Compr Canc Netw* 2014; **12**: 513-519 [PMID: 24717570 DOI: 10.6004/jnccn.2014.0056]

27 **Glynne-Jones R**, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. *BMC Cancer* 2015; **15**: 764 [PMID: 26493588 DOI: 10.1186/s12885-015-1764-1]

28 **Kim YC**, Kim JK, Kim MJ, Lee JH, Kim YB, Shin SJ. Feasibility of mesorectal vascular invasion in predicting early distant metastasis in patients with stage T3 rectal cancer based on rectal MRI. *Eur Radiol* 2016; **26**: 297-305 [PMID: 26017737 DOI: 10.1007/s00330-015-3837-6]

29 **Glynne-Jones R**, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? *Br J Cancer* 2006; **94**: 363-371 [PMID: 16465172 DOI: 10.1038/sj.bjc.6602960]

30 **Glynne-Jones R**, Anyamene N, Moran B, Harrison M. Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? *Ann Oncol* 2012; **23**: 2517-2526 [PMID: 22367706 DOI: 10.1093/annonc/mds010]

31 **Papaccio F**, Roselló S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. *Cancers (Basel)* 2020; **12** [PMID: 33287114 DOI: 10.3390/cancers12123611]

32 **Fernandez-Martos C**, Brown G, Estevan R, Salud A, Montagut C, Maurel J, Safont MJ, Aparicio J, Feliu J, Vera R, Alonso V, Gallego J, Martin M, Pera M, Sierra E, Serra J, Delgado S, Roig JV, Santos J, Pericay C. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial. *Oncologist* 2014; **19**: 1042-1043 [PMID: 25209376 DOI: 10.1634/theoncologist.2014-0233]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Dankook University Hospital.

**Informed consent statement:**All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

**Conflict-of-interest statement:** The authors have no conflicts to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 10, 2020

**First decision:** November 3, 2020

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Jiang L, Michael M, Olaoye I **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Table 1 Baseline patients’ characteristics, *n* (%)**

|  |  |
| --- | --- |
| **Characteristics** | **Total (*n* = 127)** |
| Age (yr) |  |
| Median (range) | 65 (27-92) |
| Gender  |  |
| Male | 93 (73.2) |
| Female  | 34 (26.8) |
| Performance status  |  |
|  0 | 99 (78.0) |
|  1 | 25 (19.7) |
|  2 | 3 (2.4) |
| Grade |  |
| Well differentiated | 46 (36.2) |
| Moderately differentiated | 78 (61.4) |
| Poorly differentiated | 3 (2.4) |
| Tumor location |  |
| Distal (10-15 cm from AV) | 44 (34.6) |
| Mid (5-10 cm from AV) | 48 (37.8) |
| Proximal (0-5 cm from AV) | 35 (27.6) |
| Mesorectal fascia involvement |  |
| No | 118 (92.9) |
|  Yes | 9 (7.1) |
| Extramural venous invasion |  |
| No | 50 (39.4) |
|  Yes | 41 (32.3) |
|  Unknown1 | 36 (28.3) |
| AJCC 8th T stage |  |
| cT1 | 0 |
| cT2 | 17 (13.4) |
| cT3 | 94 (74.0) |
| cT4 | 16 (12.6) |
| AJCC 8th N stage |  |
| cN0 | 7 (5.5) |
| cN+ | 120 (94.5) |
| AJCC 8th M stage |  |
| cM0 | 120 (94.5) |
| cM1 | 7 (5.5) |
| AJCC 8th stage |  |
| cI | 0 |
| cII | 7 (5.5) |
| cIII | 113 (89.0) |
| cIV | 7 (5.5) |
| Surgery |  |
| No | 34 (26.8) |
| Local excision | 3 (2.4) |
| Low anterior resection | 77 (60.6) |
| Abdominoperineal resection | 13 (10.2) |
| Adjuvant chemotherapy |  |
| No | 58 (45.7) |
| Yes | 69 (54.3) |

1Patients who did not take magnetic resonance image of the rectum. AV: Anal verge; AJCC: American Joint Committee on Cancer.

**Table 2 Summary of treatment response**

|  |  |
| --- | --- |
| **Clinical T stage** | **Pathologic T stage** |
| **ypT0** | **ypTis** | **ypT1** | **ypT2** | **ypT3** | **ypT4** |
| Scheduled surgery |
| cT2 | 2 | 0 | 1 | 6 | 4 | 0 |
| cT3 | 0 | 1 | 2 | 16 | 35 | 4 |
| cT4 | 0 | 0 | 0 | 1 | 10 | 0 |
| Unscheduled surgery |
| cT2 | 0 | 0 | 0 | 0 | 1 | 0 |
| cT3 | 1 | 0 | 0 | 3 | 3 | 1 |
| cT4 | 0 | 0 | 0 | 0 | 0 | 2 |

cT: Clinical T.

**Table 3 Pretreatment prognostic factors by univariate analysis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristics** | ***n*** | **LRC** | **DMFS** | **DFS** | **OS** |
| **Hazard ratio (95%CI)** | ***P* value** | **Hazard ratio (95%CI)** | ***P* value** | **Hazard ratio (95%CI)** | ***P* value** | **Hazard ratio (95%CI)** | ***P* value** |
| Grade |  |  |  |  |  |  |  |  |  |
| Well differentiated | 46 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Moderately differentiated | 78 | 1.202 (0.300-4.810) | 0.795 | 2.175 (0.606-7.806) | 0.233 | 1.799(0.653-4.956) | 0.256 | 4.066 (0.499-33.148) | 0.190 |
| Poorly differentiated | 3 | 10.312 (1.070-99.393) | 0.044 | 37.827 (5.655-243.040) | < 0.001 | 22.809 (4.130-125.954) | < 0.001 | 67.489 (3.594-1267.323) | 0.005 |
| Tumor location |  |  |  |  |  |  |  |  |  |
| Distal | 44 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Mid | 48 | 1.785 (0.327-9.746) | 0.527 | 1.439 (0.344-6.023) | 0.618 | 1.817 (0.547-6.039) | 0.330 | 3.244 (0.362-29.048) | 0.293 |
| Proximal | 35 | 1.781 (0.297-10.659) | 0.504 | 3.539 (0.936-13.380) | 0.063 | 3.223 (1.009-10.290) | 0.048 | 6.479 (0.755-55.611) | 0.088 |
| Tumor size |  |  |  |  |  |  |  |  |  |
|  ≤ 5 cm | 105 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| > 5 cm | 22 | 4.173 (1.120-15.551) | 0.033 | 4.224 (1.569-11.372) | 0.004 | 5.909 (2.555-13.670) | < 0.001 | 4.224 (1.569-11.372) | 0.004 |
| MRF involvement |  |  |  |  |  |  |  |  |  |
| No | 118 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
|  Yes | 9 | 2.860 (0.355-23.016) | 0.323 | 19.532 (4.787-79.695) | < 0.001 | 16.082 (5.022-51.503) | < 0.001 | 19.532 (4.787-79.695) | < 0.001 |
| T3 substage |  |  |  |  |  |  |  |  |  |
|  T3a or b | 46 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
|  T3c or d | 48 | 70.381 (0.053-94343.482) | 0.247 | 5.272 (1.073-25.898) | 0.041 | 7.852 (1.710-36.052) | 0.008 | 5.272 (1.073-25.898) | 0.041 |
| EMVI1 |  |  |  |  |  |  |  |  |  |
| No | 50 | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
|  Yes | 41 | 11.428 (1.402-93.177) | 0.023 | 4.408 (1.488-13.056) | 0.007 | 4.387 (1.843-12.692) | 0.001 | 4.408 (1.488-13.056) | 0.007 |
| Superior rectal lymph node |  | 1.253 (0.973-1.614) | 0.081 | 1.102 (0.870-1.395) | 0.420 | 1.208 (1.005-1.451) | 0.044 | 1.102 (0.870-1.395) | 0.420 |

1Patients who did not take magnetic resonance image of the rectum were excluded. MRF: Mesorectal fascia; EMVI: Extramural venous invasion; LRC: Locoregional contro; DMFS: Distant metastasis-free survival; DFS: Disease-free survival; OS: Overall survival.

**Table 4 Predictive factors for early distant metastasis, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | **Early metastasis** | ***P* value** |
| **Yes (*n* = 5)** | **No (*n* = 122)** |
| Grade |  |  | 0.025 |
| Well differentiated | 3 (60.0) | 43 (35.2) |  |
| Moderately differentiated | 1 (20.0) | 77 (63.1) |  |
| Poorly differentiated | 1 (20.0) | 2 (1.6) |  |
| Tumor location |  |  | 0.031 |
| Distal | 0 | 44 (36.1) |  |
| Mid | 1 (20.0) | 47 (38.5) |  |
| Proximal | 4 (80.0) | 31 (25.4) |  |
| MRF involvement |  |  | 0.002 |
| No | 2 (40.0) | 116 (95.1) |  |
|  Yes | 3 (60.0) | 6 (4.9) |  |
| EMVI1 |  |  | 0.012 |
| No | 0 | 50 (58.1) |  |
|  Yes | 5 (100) | 36 (41.9) |  |

1Patients who did not take magnetic resonance image of the rectum were excluded. MRF: Mesorectal fascia; EMVI: Extramural venous invasion.

**Table 5 Summaries of studies on neoadjuvant chemotherapy followed by chemoradiotherapy**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Design** | ***n*** | **Eligibility** | **NAC regimen** | **CRT regimen** | **AC regimen** | **Response** | **Compliance** | **Recurrence** | **Survival** |
| Chau *et al*[[3](#_ENREF_3)] | Prospective single-arm | 36 | cT3N0-2; cT4N0-2 | MMC (× 2); PVI 5-FU | RT 54Gy/30Fx’s; PVI 5-FU | MMC; PVI 5-FU | 27.8%1 after NAC;80.6%1 after CRT  | NAC 100%; CRT 100% | LR 2 pts; DM 9 pts | 1Y-OS 93.5%; 2Y-OS 70.3% |
| EXPERT[[4](#_ENREF_4),[5](#_ENREF_5)]  | Phase II single-arm | 105 | MR defined disease: MRF involved or threatened, cT3 tumor at or below the levators, cT4, cN2, extramural extension ≥ 5 mm | CAPOX (× 4) | RT 54Gy/30Fx’s; capecitabine | capecitabine | 74%1 after NAC;89%1 after CRT  | NAC 89%; CRT 91% | LR 6 pts; DM 21 pts | 5Y-OS 75.0% |
| GCR-3[[6](#_ENREF_6),[7](#_ENREF_7)]  | Phase II; RCT | 54 | MR defined disease: Distal edge within 12 cm from AV, lower third cT3, resectable cT4, cT3-4N+, MRF involved or threatened | CAPOX (× 4) | RT 54Gy/27Fx’s; CAPOX | - | Downstaging 43.0%; pCR 14.0% | NAC 94.0%; CRT 85.0% | LR 5%; DM 23% | 5Y-OS 75.0% |
| 49 | - | RT 54Gy/27Fx’s; CAPOX | CAPOX (× 4) | Downstaging 58.0%; pCR 13.0% | CRT 80.0%; AC 57.0% | LR 2%; DM 21% | 5Y-OS 78.0% |
| COPERNICUS[[8](#_ENREF_8)] | Phase II single-arm | 60 | Inferior margin ≥ 4 cm from AV, superior margin < S1/2 interspace, tumor > 1 mm from MRF, cT3d, cT4, mrT3a-b with either EMV invasion or mesorectal lymph nodes  | Oxaliplatin/5-FU (× 4) | RT 25Gy/5Fx’s | Oxaliplatin 5-FU (× 8) | T down staging: 73.0%1 after NAC;74.0% after surgery  | NAC 75.0%; AC 37.0% | LR 2 pts; DM 6 pts | 2Y-PFS 86.2% |
| CONTRE[[9](#_ENREF_9)] | Prospective single-arm | 39 | cT3-4N0, cT1-4N+ | mFOLFOX6 (× 8) | RT 50.4Gy/28Fx’s capecitabine | - | pCR 33.0% | NAC 92.0% | LR 2 pts; DM 6 pts | - |
| Schou *et al*[[10](#_ENREF_10)] | Prospective single-arm | 84 | MR defined disease: MRF involved or threatened, cT3-4 N+ | CAPOX (× 2) | RT 54Gy/27Fx’scapecitabine | - | T down staging 69%after surgerypCR 23.0% | NAC 88.0% | LR 1%DM 25% | 5Y-OS 67.0% |
| Dueland *et al*[[11](#_ENREF_11)] | Prospective single-arm | 97 | cT3 with < 3 mm from MRF, cT4, N+, resectable synchronous metastasis | Nordic FLOX (× 2) | RT 50Gy/25Fx’s; CAPOX | - | pCR 17.3% | NAC 91.0% | LR 4 pts; DM 27 pts | 5Y-OS 83.0% |
| Koeberle *et al*[[12](#_ENREF_12)] | Phase II single-arm | 60 | cT3-4 with N- or N+ | CAPOX (× 1) | RT 45Gy/25Fx’s; CAPOX | - | pCR 23.0% | Oxaliplatin 87.0% | - | - |
| Maréchal *et al*[[13](#_ENREF_13)] | Phase II RCT | 29 | cT2-4, cN+ | - | RT 45Gy/25Fx’s; 5-FU | - | pCR 28% | NAC 96.0%; CRT 98.0% | - | - |
| 28 | mFOLFOX6 (× 2) | RT 45Gy/25Fx’s; 5-FU | - | pCR 25% |
| EXPERT-C[[14](#_ENREF_14)] | Phase II RCT | 81 | MR defined disease: Tumor within 1mm of MRF, cT3 tumor at or below the levators, cT4, presence of EMV invasion, extramural extension$\geq $5mm | CAPOX (× 4) cetuximab | RT 54Gy/30Fx’s; capecitabine/ cetuximab | CAPOX (× 4); cetuximab | 64.0%1 after NAC;84.0%1 after CRT  | NAC 95.0%; CRT 91.0% | LR 1pt | - |
| 83 | CAPOX (× 4) | RT 54Gy/30Fx’s; capecitabine | CAPOX (x4) | 54.0%1 after NAC;76.0%1 after CRT  | NAC 93.0%; CRT 90.0% | LR 2 pts | - |
| AVACROSS[[15](#_ENREF_15)] | Phase II single-arm | 47 | Distal edge ≤ 1 cm from AV, cT3N+, resectable cT4, cT3 tumor in lower third, tumor in middle third with ≤ 2 mm from MRF, N+ with ≤ 2 mm from MRF | CAPOX/bevacizumab (× 4) | RT 50Gy/25Fx’s; capecitabine/ bevacizumab | CAPOX (x4) | pCR 34.0% | NAC 85.0%; CRT 83.0% | DM 5 pts | - |
| Eisterer *et al*[[16](#_ENREF_16)]  | Phase II single-arm | 25 | MR defined disease: cT3 (< 5 mm from MRF), cT4 | CAPOX/bevacizumab (× 3) | RT 45Gy/25Fx’s capecitabine | - | pCR 25.0% | NAC 79.2%CRT 94.7% | - | - |
| PRODIGE23[[31](#_ENREF_31)] | Phase III | 231 | cT3-4  | mFOLFIRINOX (× 6) | RT 50Gy25Fx’s; capecitabine | mFOLFOX6 or capecitabine | pCR 27.8% | - | - | 3Y-DFS 75.7% |
| 230 | - | pCR 12% | - | - | 3Y-DFS 68.5% |

1Tumor response evaluation by imaging. NAC: Neoadjuvant chemotherapy; CRT: Chemoradiotherapy; RT: Radiotherapy; AC: Adjuvant chemotherapy; OS: Overall survival; PFS: Progression-free survival; LR: Local recurrence; DM: Distant metastasis; MR: Magnetic resonse; AV: Anal verge; MRF: Mesorectal fascia; EMV: Extramural venous; MMC: Mitomycin C; PVI: Protracted venous infusion; CAPOX: Capecitabine/oxaliplatin; FLOX: Oxaliplatin/5-FU; FOLFIRINOX: Oxaliplatin/5-FU/Irinotecan; pCR: Pathological complete response; RCT: Randomized controlled trial.

**Table** **6** **Summaries of studies on neoadjuvant chemotherapy without radiotherapy**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Design** | ***n*** | **Eligibility** | **NAC regimen** | **CRT regimen** | **AC regimen** | **Response** | **Compliance** | **Recurrence** | **Survival** |
| Koizumi *et al*[[17](#_ENREF_17)] | Phase II single-arm | 30 | Lower edge under S2, cT3-4 | FOLFOX (× 6) | - | - | pCR 6.7% | NAC 93.3% | LR 2 pts; DM 5 pts | 3Y-OS 95.7% |
| FORTUNE[[18](#_ENREF_18)] | Phase II single-arm | 106 | cT3-4, cN1-2, distal edge < 12 cm from AV | mFOLFOXIRI (× 4-6) | RT 50.4Gy/28Fx’s; mFOLFOX61 or RT 25Gy/5Fx’s | mFOLFOX6(× 6) | pCR 20.4%; pCR 17.4% after NAC | NAC 100% | - | - |
| Ishii *et al*[[19](#_ENREF_19)] | Prospectivesingle-arm | 26 | cT3-4 with cN0-2 | IFL (× 2) | - | - | Downstaging 57.0%; pCR 3.8% | NAC 100% | - | 5Y-OS 84.0% |
| FOWARC[[20](#_ENREF_20),[21](#_ENREF_21)] | Phase III RCT | 165 | cT3-4, N1-2 | - | RT 45Gy/25Fx’s 5-FU | 5-FU (× 7) | pCR 14.0% | CRT 88.4% | LR 8.0% | 3Y-OS 91.3% |
| 165 | - | RT 45Gy/25Fx’s mFOLFOX6 | mFOLFOX (× 7) | pCR 27.5% | CRT 94.9% | LR 7.0% | 3Y-OS 89.1% |
| 165 | mFOLFOX6 (× 4-6) | - | mFOLFOX6(× 6-8) | pCR 6.5% | NAC 94.5% | LR 8.3% | 3Y-OS 90.7% |
| Schrag *et al*[[22](#_ENREF_22)] | Phase II single-arm | 32 | Distal edge within 5-12cm from AV, cT3N-, cT3N+ | mFOLFOX6/bevacizumab (× 6) | RT 50.4Gy/28Fx’s 5-FU1 | FOLFOX | pCR 25.0% | NAC 93.8% | LR 0; DM 12.5% | 4Y-OS 91.0% |
| N-SOG 03[[23](#_ENREF_23)] | Phase II single-arm | 32 | MR defined disease: Inferior margin below the S2 lower margin, MRF involved or threatened, cT3b-d, cT4, cN2 | CAPOX/bevacizumab (× 4) | - | - | T down staging 54.0% after surgery pCR 25.0% | NAC 79.2%; CRT 94.7% | - | - |
| GEMCAD 0801[[24](#_ENREF_24),[32](#_ENREF_32)] | Phase II single-arm | 46 | MR defined disease: Distal edge > 5 cm from AV, cT3 (≥ 2 mm from MRF) | CAPOX/bevacizumab (× 4) | - | - | pCR 19.5% | NAC 95.6% | LR 2 pts; DM 8 pts; Both 1 pt | - |

1Chemoradiotherapy if any progression after neoadjuvant chemotherapy. NAC: Neoadjuvant chemotherapy; CRT: Chemoradiotherapy; RT: Radiotherapy; AC: Adjuvant chemotherapy; OS: Overall survival; LR: Local recurrence; DM: Distant metastasis; MR: Magnetic resonse; AV: Anal verge; MRF: Mesorectal fascia; CAPOX: Capecitabine/oxaliplatin; IFL: Irinotecal/fluorouracil/leukovorin; pCR: Pathological complete response; RCT: Randomized controlled trial.